AR128113A1 - Composiciones que contienen fexofenadina - Google Patents
Composiciones que contienen fexofenadinaInfo
- Publication number
- AR128113A1 AR128113A1 ARP220103594A ARP220103594A AR128113A1 AR 128113 A1 AR128113 A1 AR 128113A1 AR P220103594 A ARP220103594 A AR P220103594A AR P220103594 A ARP220103594 A AR P220103594A AR 128113 A1 AR128113 A1 AR 128113A1
- Authority
- AR
- Argentina
- Prior art keywords
- fexofenadine
- compositions containing
- zwitterion
- dihydrate
- containing fexofenadine
- Prior art date
Links
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003592 fexofenadine Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000004683 dihydrates Chemical class 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2021/000916 WO2023126637A1 (en) | 2021-12-29 | 2021-12-29 | Compositions containing fexofenadine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128113A1 true AR128113A1 (es) | 2024-03-27 |
Family
ID=80122351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103594A AR128113A1 (es) | 2021-12-29 | 2022-12-27 | Composiciones que contienen fexofenadina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250082623A1 (https=) |
| EP (1) | EP4456880B1 (https=) |
| JP (1) | JP7826492B2 (https=) |
| KR (1) | KR20240136358A (https=) |
| CN (1) | CN118715004A (https=) |
| AR (1) | AR128113A1 (https=) |
| AU (1) | AU2021480621A1 (https=) |
| CA (1) | CA3242293A1 (https=) |
| CO (1) | CO2024009774A2 (https=) |
| MX (1) | MX2024008242A (https=) |
| PE (1) | PE20242355A1 (https=) |
| WO (1) | WO2023126637A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026074306A1 (en) | 2024-10-03 | 2026-04-09 | Opella Healthcare Group Sas | Chewable fexofenadine tablets |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| DOP2006000274A (es) * | 2005-12-14 | 2007-10-15 | Sanofi Aventis Us Llc | Formulación de suspensión de fexofenadina |
| CN102958515A (zh) * | 2009-12-02 | 2013-03-06 | 阿普塔利斯制药有限公司 | 非索非那定微胶囊及含有非索非那定微胶囊的组合物 |
| FR2959130A1 (fr) * | 2010-04-21 | 2011-10-28 | Sanofi Aventis | Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant. |
| CN102512389B (zh) * | 2011-12-27 | 2013-08-21 | 天津市嵩锐医药科技有限公司 | 非索非那定盐酸盐口腔崩解药物组合物 |
| KR101761983B1 (ko) * | 2014-08-25 | 2017-08-07 | 아주대학교산학협력단 | 구강내 속붕해 필름 조성물 및 그 제조방법 |
| CN105997910A (zh) * | 2016-06-09 | 2016-10-12 | 北京化工大学 | 一种掩味制剂及其制备方法 |
-
2021
- 2021-12-29 KR KR1020247025570A patent/KR20240136358A/ko active Pending
- 2021-12-29 PE PE2024001517A patent/PE20242355A1/es unknown
- 2021-12-29 CN CN202180105441.6A patent/CN118715004A/zh active Pending
- 2021-12-29 CA CA3242293A patent/CA3242293A1/en active Pending
- 2021-12-29 AU AU2021480621A patent/AU2021480621A1/en active Pending
- 2021-12-29 MX MX2024008242A patent/MX2024008242A/es unknown
- 2021-12-29 EP EP21851701.9A patent/EP4456880B1/en active Active
- 2021-12-29 JP JP2024539614A patent/JP7826492B2/ja active Active
- 2021-12-29 US US18/725,446 patent/US20250082623A1/en active Pending
- 2021-12-29 WO PCT/IB2021/000916 patent/WO2023126637A1/en not_active Ceased
-
2022
- 2022-12-27 AR ARP220103594A patent/AR128113A1/es unknown
-
2024
- 2024-07-23 CO CONC2024/0009774A patent/CO2024009774A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3242293A1 (en) | 2023-07-06 |
| JP7826492B2 (ja) | 2026-03-09 |
| EP4456880B1 (en) | 2026-03-18 |
| AU2021480621A1 (en) | 2024-07-18 |
| CN118715004A (zh) | 2024-09-27 |
| WO2023126637A1 (en) | 2023-07-06 |
| PE20242355A1 (es) | 2024-12-16 |
| MX2024008242A (es) | 2024-07-19 |
| CO2024009774A2 (es) | 2024-08-08 |
| US20250082623A1 (en) | 2025-03-13 |
| EP4456880A1 (en) | 2024-11-06 |
| KR20240136358A (ko) | 2024-09-13 |
| JP2024546513A (ja) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000252A (es) | Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1 | |
| CL2022002695A1 (es) | Inhibidores de rip1k | |
| CO6251277A2 (es) | Inhibidor de la dpp-iv combinado con mas de un agente antidiabetico, comprimidos que comprenden tales formulaciones, su uso y procedimientos para su preparación. | |
| MX2020011868A (es) | Inhibidores de los receptores erbb. | |
| DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| PE20241305A1 (es) | Analogos de amilina | |
| MX2024003236A (es) | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. | |
| CL2008002768A1 (es) | Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades. | |
| CL2021002447A1 (es) | (divisional de solicitud 2218-2019) formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
| MX2019003099A (es) | Composicion farmaceutica. | |
| ECSP20063701A (es) | Formulación sólida de mezclas insecticidas | |
| WO2019073331A3 (en) | Pharmaceutical compositions of apremilast | |
| AR045193A1 (es) | Composicion de fexofenadina y proceso de preparacion | |
| AR128113A1 (es) | Composiciones que contienen fexofenadina | |
| BR112022007207A2 (pt) | Composição farmacêutica que compreende selexipag | |
| CL2022003812A1 (es) | Inhibidores de rip1k | |
| HN2003000162A (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen. | |
| PE20241347A1 (es) | MODULAR LA EXPRESION DE APOLIPOPROTEINA (a) | |
| CO5280222A1 (es) | Composicion farmaceutica que comprende pemetrexed | |
| NO20080552L (no) | GLP-1 farmasoytiske sammensetninger | |
| CL2023000200A1 (es) | Nuevo derivado de pirazol | |
| HN2012001923A (es) | Hidrato del hidrocloruro de agomelatina y preparacopn de este |